Gattex (teduglutide) / Takeda - LARVOL DELTA

Real-world effectiveness and safety of teduglutide in adult and pediatric patients with short bowel syndrome in Argentina. (PubMed, World J Gastrointest Pharmacol Ther) - "This prospective real-world study demonstrated the effectiveness and safety of teduglutide in adult and pediatric patients with SBS in Argentina. The clinical response observed in both adults and pediatric patients was greater than that reported in phase 3 trials and was consistent with the results of other real-world studies."

Journal • Real-world evidence • Gastrointestinal Disorder • Pain • Pediatrics • Short Bowel Syndrome

Positive clinical outcomes associated with use of glucagon-like peptide-2 (GLP-2) analogues in patients with Intestinal Failure: a systematic review and meta-analysis. (PubMed, Clin Nutr ESPEN) - "Teduglutide appears to be an acceptable therapy, with a discontinuation rate of 14%. Early reports suggest similar benefits for emerging GLP-2 including glepaglutide and apraglutide."

Clinical data • Journal • Retrospective data • Gastrointestinal Disorder • Short Bowel Syndrome

Six-Month Safety and Effectiveness of Teduglutide in Patients with Short Bowel Syndrome in Japan: Interim Analysis of Post-marketing Surveillance. (PubMed, Adv Ther) - P | "In this interim analysis of a 36-month PMS, teduglutide demonstrated an acceptable safety profile and promising effectiveness in patients with SBS."

Journal • P4 data • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Pain • Pediatrics • Short Bowel Syndrome

3, 2, 1! From GLP-2 to GLP-1 analog over a 10-year journey. (PubMed, Endocrinol Diabetes Nutr (Engl Ed)) - "This allowed for a surgical reconstruction, after which she achieved full enteral autonomy, later developing grade 1 obesity. This case highlights the therapeutic potential of teduglutide as a bridging therapy and the remaining uncertainties regarding its long-term management."

Journal • Review • Gastrointestinal Disorder • Genetic Disorders • Obesity • Short Bowel Syndrome

Delayed presentation of a retained colonic segment in a child with intestinal failure on teduglutide. (PubMed, JPGN Rep) - "Despite relatively few reported side effects, there is a theoretical risk of proliferative complications. Here we present an intriguing case of a pediatric patient found to have a decade-long retained, discontinuous segment of colon from a surgical procedure performed in infancy, which became clinically significant after a period of treatment with teduglutide."

Journal • Gastrointestinal Disorder • Pediatrics • Short Bowel Syndrome

Multifactorial Kidney Transplant Failure in a Patient with Short-Bowel Syndrome (KIDNEY WEEK 2025) - "Previous studies have shown the benefit of diet modifications before and after transplant to reduce oxaluria. Teduglutide, a GLP-2 analog, has shown benefit in treating both SBS and its associated kidney failure in post transplant patients."

Clinical • Chronic Kidney Disease • Gastrointestinal Disorder • Metabolic Disorders • Nephrology • Renal Calculi • Short Bowel Syndrome • Transplant Rejection • Transplantation

"Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey" (DGHO 2025) - "Our retrospective analysis suggests that teduglutide is safe and has activity in a fraction of patients with intestinal SR-aGvHD, which needs validation in a prospective trial."

Clinical • Acute Graft versus Host Disease • Graft versus Host Disease • Immunology

Development of a consensus parenteral solution weaning algorithm for children with short-bowel syndrome associated intestinal failure responding to teduglutide therapy. (PubMed, Arch Dis Child) - "Future studies will be required to validate the algorithm."

Journal • Gastrointestinal Disorder • Pediatrics • Short Bowel Syndrome

Risks of Gastrointestinal Malignancies in Short Bowel Syndrome Patients Treated With Teduglutide: Results From TriNetX (ACG 2025) - "Post-matching, cohorts were balanced for demographics and comorbidities. Mean follow-up time was 950 days in the teduglutide group vs. 1,219 days in the control group."

Clinical • Colon Cancer • Colorectal Cancer • Esophageal Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Oncology • Pancreatic Cancer • Short Bowel Syndrome • Small Intestinal Carcinoma • Solid Tumor

Vedolizumab for Severe Refractory Acute Cellular Rejection After Intestinal Transplantation (ACG 2025) - "He was continued on teduglutide, a glucagon-like peptide 2 analog (GLP-2) post-transplant and presented for diverting loop ileostomy reversal four months post-ITx...He was discharged on a prednisone taper with ongoing tacrolimus and monthly basiliximab...He received IV VDZ 300 mg, eculizumab 900 mg, and methylprednisolone 500 mg...Our patient responded rapidly to VDZ after failing high-dose methylprednisolone, infliximab and basiliximab...Additionally, we postulate that GLP-2 analogs used in the post-transplant period may aid epithelial protection and mucosal recovery during ACR. Further studies are needed to assess long-term efficacy and safety of VDZ in this setting.Figure: Figure 1: Progressive improvement of duodenal graft mucosa from denuded, edematous and inflamed mucosa (A) to recovery of epithelial cells and villi (yellow arrow) (B, C) to complete re-epithelization (D); Improvement of ascending colon graft from denuded and ulcerated mucosa (E) to formation of..."

Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Peptic Ulcer • Short Bowel Syndrome • Transplant Rejection • Transplantation • CD52 • IL2 • ITGA4 • TNFA

Glucagon-Like Peptide Peptide-2 (GLP-2) Agonists for Patients With Short Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (ACG 2025) - "Our meta-analysis of six RCTs comprising 470 patients demonstrated that GLP-2 agonists significantly reduced PS volume from baseline compared to placebo (MD -251; 95% CI: -363- -139; I2 = 0%). Subgroup analyses confirmed consistent reductions in PS volume with Teduglutide and Glepaglutide, but not with Apraglutide (MD -93; 95% CI: -344 - 156). Furthermore, GLP-2 agonists nearly doubled the number of responders (defined as a ≥20% reduction in PS volume) compared to placebo (RR 1.97; 95% CI: 1.47, 2.64; I2 = 0%)."

Retrospective data • Review • Gastrointestinal Disorder • Short Bowel Syndrome

Safety of Teduglutide for Managing Patients with Short Bowel Syndrome: A Systematic Review and Meta-analysis. (PubMed, Pak J Med Sci) - "While the drug presents an essential therapeutic option, healthcare professionals must carefully monitor the occurrence of these side effects. CRD42023447985."

Journal • Retrospective data • Review • Gastrointestinal Disorder • Infectious Disease • Nephrology • Respiratory Diseases • Septic Shock • Short Bowel Syndrome

A real-world pharmacovigilance assessment of drug-related carcinoembryonic antigen increase. (PubMed, Medicine (Baltimore)) - "And dacomitinib, regorafenib, fruquintinib, vandetanib, and panitumumab were the top 5 drugs with high risk. Non-antitumor drugs were all moderate risk, involving atorvastatin, zoledronic acid, amiodarone hydrochloride, lithium, and teduglutide...The number of related adverse event reports increased year by year. The results of this study provided the relevant basis for pharmacovigilance, and provided the basis for strengthening drug safety and making correct drug decision in clinical practice."

Adverse events • Journal • Real-world evidence • Oncology • CEACAM5

A case report on the long-term use of teduglutide in a pediatric patient with short bowel syndrome. (PubMed, Nutr Clin Pract) - "Although the response was slower than in previously reported cases, long-term TED administration led to favorable outcomes, including PN independence. This case underscores the potential for TED to support intestinal adaptation over extended periods and highlights the importance of individualized, long-term treatment strategies in managing severe pediatric SBS."

Journal • Gastrointestinal Disorder • Infectious Disease • Pediatrics • Short Bowel Syndrome

Efficacy of Teduglutide in Pediatric Short Bowel Syndrome: Association with Citrulline Levels and Anatomical Location of Remnant Small Intestine. (PubMed, Children (Basel)) - "However, the magnitude of the citrulline change varied across bowel anatomy types, suggesting that the anatomical difference in the remnant bowel may influence the biomarker response. Further detailed pediatric cases are required to clarify the role of citrulline in evaluating GLP-2 analogue treatment outcomes."

Journal • Gastrointestinal Disorder • Pediatrics • Short Bowel Syndrome

Longitudinal single-cell analysis of glucagon-like peptide-2 treatment in the patients with short bowel syndrome. (PubMed, JCI Insight) - "The study findings indicate that GLP-2 analogs reshape intestinal immunity and microbiota, fostering a less inflammatory environment while promoting nutrient uptake efficiency. These insights offer a deeper understanding of the role of GLP-2 analogs in gut adaptation and provide a foundation for refining clinical strategies for SBS treatment."

Journal • Gastrointestinal Disorder • Short Bowel Syndrome • TOP1 • TOP2A

Teduglutide treatment during breast feeding in a patient with intestinal failure: a case report. (PubMed, Front Nutr) - No abstract available

Journal

Quality of life and lived experience of patients with short bowel syndrome treated with teduglutide and weaning off home parenteral nutrition: a qualitative analysis of patient diaries. (PubMed, BMJ Open Gastroenterol) - "This study provides valuable insights into the lived experiences and coping strategies of patients with SBS prescribed teduglutide to wean off PN. The findings underscore the importance of healthcare teams understanding these everyday challenges to facilitate shared decision-making and tailor care plans. Further research is needed to explore the long-term impact of teduglutide on QOL, including the validation of tools to screen for fatigue-related emotional distress and the development of targeted interventions to support patients during the weaning process."

HEOR • Journal • Fatigue • Gastrointestinal Disorder • Short Bowel Syndrome

Reduction of Parenteral Nutrition in Children with Short Bowel Syndrome Treated with Teduglutide: Experience from the Czech Republic. (PubMed, Klin Padiatr) - "They also validate its safety and efficacy in this population. Despite the reduction in PN, improvements in weight were evident across the entire patient cohort."

Journal • Gastrointestinal Disorder • Pediatrics • Short Bowel Syndrome

Glucagon-Like Peptide-2 Therapy Outcomes Following Intestinal and Multivisceral Transplantation: A Multicenter Experience (WTC 2025) - "All patients received teduglutide, with 57% starting treatment prior to undergoing IT... GLP-2 therapy may play a beneficial role in intestinal adaptation and post-transplant recovery, potentially facilitating independence from TPN in IT and MVT recipients. Bowel obstruction appears to be the main complication leading to therapy discontinuation and occurred in the majority of patients undergoing GLP-2 therapy. Despite these challenges, survival outcomes were generally favorable, warranting further investigation into the long-term benefits and risks of GLP-2 therapy in transplant recipients."

Clinical • Colon Cancer • Colonic Polyps • Colorectal Cancer • Gastroenterology • Gastrointestinal Disorder • Septic Shock • Short Bowel Syndrome • Solid Tumor • Transplantation

Predictors of response and enteral autonomy in children with short bowel syndrome treated with teduglutide: a real-life multicentre cohort study. (PubMed, EClinicalMedicine) - "Between 01.06.2021 and 31.05.2023, we collected information on 104 children (64 males, 61.5%; 40 females, 38.5%) the median age at enrolment was 6.7 years old (IQR: 3.6-10.4); at 12 months' follow up after TED start 68 children achieved response (cumulative incidence: 70%, 95% CI 61%-79%), whereas complete PN weaning was achieved in 21 children (cumulative incidence: 22%, 95% CI 15%-31%). Even if limited by the real-life design of the study, these findings may guide a tailored indication for the use of teduglutide in children with short bowel syndrome. The European Society of Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) Networking grant."

Journal • Gastrointestinal Disorder • Hepatology • Liver Failure • Pediatrics • Short Bowel Syndrome

The impact and risk of teduglutide on reducing parenteral support in adult short bowel patients: UK tertiary centre data (BSG 2025) - "We also report the development of a vulval cancer occurring after only 7 months treatment. These encouraging results support results from previous studies and indicate significant benefits from tedaglutide use"

Clinical • Gastrointestinal Disorder • Gynecologic Cancers • Oncology • Short Bowel Syndrome • Solid Tumor • Vulvar Cancer

TAK-633-3009: A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome (clinicaltrials.gov) - P3 | N=13 | Recruiting | Sponsor: Takeda | Not yet recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Disorder • Short Bowel Syndrome

Teduglutide in adults with short bowel syndrome and intestinal failure: A descriptive cohort study. (PubMed, JPEN J Parenter Enteral Nutr) - "Within an Australian cohort, teduglutide is effective at reducing parenteral support requirements in patients with short bowel syndrome-intestinal failure, although the effect onset and range remains heterogenous."

Journal • Gastrointestinal Disorder • Short Bowel Syndrome

Incorporating Caregiver Burden in Japans Cost-Effectiveness Evaluation: A Case Study of Teduglutide for Pediatric Short Bowel Syndrome (ISPOR 2025) - "This study aimed to integrate caregiver burden into cost-effectiveness evaluations within Japan’s healthcare system, using teduglutide, a recombinant human glucagon-like peptide 2 analogue that reduces PS dependence, as a case study. This study illustrates the practical steps for incorporating caregiver burden into Japan’s cost-effectiveness analyses, using pediatric SBS as an example. This expanded analysis captures a broader value, potentially guiding more informed resource allocation in Japan’s healthcare context."

Case study • Clinical • Cost effectiveness • HEOR • Gastrointestinal Disorder • Pediatrics • Short Bowel Syndrome